+ All Categories
Home > Documents > 5 IPC SYMPOSIUM Advances in transplant and...

5 IPC SYMPOSIUM Advances in transplant and...

Date post: 06-Jul-2020
Category:
Upload: others
View: 3 times
Download: 0 times
Share this document with a friend
5
5 TH IPC SYMPOSIUM Advances in transplant and cellular immunotherapy Organizers: Prof Didier Blaise, Paoli-Calmettes Institute, Marseille & Prof Mohamad Mohty, Saint-Antoine Hospital, Paris, France This event is endorsed by: www.marseille-symposium.com NOVEMBER 15-17 2019 PALAIS DU PHARO MARSEILLE FRANCE
Transcript

5TH IPC SYMPOSIUM Advances in transplant and cellular immunotherapy

Organizers: Prof Didier Blaise, Paoli-Calmettes Institute, Marseille & Prof Mohamad Mohty, Saint-Antoine Hospital, Paris, France

This event is endorsed by:

www.marseille-symposium.com

NOVEMBER

15 -172019PALAIS DU PHARO

MARSEILLEFRANCE

FINAL PROGRAM 5TH IPC SYMPOSIUM Advances in transplant

and cellular immunotherapy

FRIDAY, NOVEMBER 15, 2019

08.00 ACUTE LEUKEMIA 16.00 WORKING PARTY

16.00 SESSION 1 – IMMUNOLOGY Chairs: A-S. Chrétien, Marseille, France,

L. Luznik, Baltimore, USA & J. Sanz, Valencia, Spain

16.00 Gamma-delta T cells D. Olive, Marseille, France

16.30 T-reg cells S. Parmar, Houston, USA

17.00 Microbiote as tool of immunomodulation F. Malard, Paris, France

17.30 Extracellular vesicles as biomarkers acute graft-versus-host disease after haplo-identical allografting with post-transplant cyclophosphamide G. Lia, Turin, Italy

18.00 Coffee break & exhibition visit

Chairs: K. Liu, Beijing, China & J. Versluis, Rotterdam, The Netherlands

18.15 Antitumor vaccination: still a topic? How? E. Fuchs, Baltimore, USA

18.45 HLA on leukemic cells after transplant L. Vago, Milano, Italy

19.15 Discussion 19.30 End of sessions

FAC

ULT

IES

Borje Andersson, Houston, USA

Jacques-Olivier Bay, Clermont-Ferrand, France

Ali Bazarbachi, Beirut, Lebanon

Didier Blaise, Marseille, France

Stefania Bramanti, Milan, Italy

Eolia Brissot, Paris, France

Luca Castagna, Milan, Italy

Christian Chabannon, Marseille, France

Anne-Sophie Chrétien, Marseille, France

Patrice Chevallier, Nantes, France

Raynier Devillier, Marseille, France

Rémy Dulery, Paris, France

Jean El Cheikh, Beirut, Lebanon

Martin Ferrando, Montevideo, Uruguay

Ephraim Fuchs, Baltimore, USA

Sabine Fürst, Marseille, France

Raùl Gabus, Montevideo, Uruguay

Jordan Gauthier, Seattle, USA

Norbert-Claude Gorin, Paris, France

Ivana Gojo, Baltimore, USA

Kazimierz Halaburda, Warsaw, Poland Samia Harbi, Marseille, France

Thomas Heinicke, Magdeburg, Germany

Jiong Hu, Shanghai, China

Xiao Jun Huang, Beijing, China

Surapol Issaragrisil, Bangkok, Thailand

Guiseppe Lia, Turin, Italy

Kaiyan Liu, Beijing, China

Francesca Lorentino, Milan, Italy Leo Luznik, Baltimore, USA

Florent Malard, Paris, France

Mohamad Mohty, Paris, France

Razan Mohty, Beirut, Lebanon

Arnon Nagler, Tel Hashomer, Israel

Daniel Olive, Marseille, France

Simrit Parmar, Houston, USA

Zinaida Peric, Zagreb, Croatia

Finn Petersen, Boise, USA

Jaime Sanz, Valencia, Spain

Álvaro Urbano-Ispizua, Barcelona, Spain

Luca Vago, Milan, Italy

Alberto Vazquez, Montevideo, Uruguay

Jurjen Versluis, Rotterdam, The Netherlands Ling Wang, Shanghai, China Ibrahim Yakoub-Agha, Lille, France

Hu Yongxian, Hangzhou, China

FINAL PROGRAM

15.45 SESSION 5 – CAR T-CELLS (1) Chairs: R. Gabus, Montevideo, Uruguay

& F. Malard, Paris, France

15.45 Present status of Car T-cells in Europe C. Chabannon, Marseille, France

16.15 Car T-cells complications I. Yakoub-Agha, Lille, France

16.45 Coffee break & exhibition visit

17.15 SESSION 6 – CAR T CELLS (2) Chairs: S. Fürst, Marseille, France,

J. Gauthier, Seattle, USA & H. Yongxian, Hangzhou, China

17.15 Car T-cells for multiple myeloma M. Mohty, Paris, France

17.45 Car T-cells: the Barcelona experience A. Urbano-Ispizua, Barcelona, Spain

18.15 Can cellular immunotherapy be brought to patientsliving far from academic medical centers? F. Petersen, Boise, USA

18.45 Discussion 19.00 End of sessions

20.30 Congress dinner

08.30 Welcome address

09.00 SESSION 2 – MYELOID MALIGNANCIES Chairs: N-C. Gorin, Paris, France,

A. Vazquez, Montevideo, Uruguay & L. Wang, Shanghai, China

09.00 The place of Haplo-HSCT in myeloid malignancies in Europe A. Nagler, Tel Hashomer, Israel

09.30 Haplo HSCT for AML R. Devillier, Marseille, France

10.00 Acute leukemia relapse after Allo-HSCT: new insights in prevention and treatment I. Gojo, Baltimore, USA

10.30 Haplo-HSCT for MDS D. Blaise, Marseille, France

11.00 Coffee break & exhibition visit

11.30 SESSION 3 – ALL Chairs: J. El Cheikh, Beirut, Lebanon

& T. Heinicke, Magdeburg, Germany

11.30 R/R ALL best approach? Monoclonal antibodies E. Brissot, Paris, France

12.00 R/R ALL best approach? Car T-cells J. Gauthier, Seattle, USA

12.30 Lunch & exhibition visit

14.00 SESSION 4 – UPDATE ON TRANSPLANT Chairs: J-O. Bay, Clermont-Ferrand, France,

S. Isaragrissil, Bangkok, Thailand & M. Ferrando, Montevideo, Uruguay

14.00 Recent updates in Beijing Haplo-HSCT protocol X. J. Huang, Beijing, China

14.30 Post-transplant cyclosphosphamide: GVL without GVHD? L. Luznik, Baltimore, USA

15.00 Sequential targeted myeloablation for myeloid malignancies B. Andersson, Houston, USA

15.30 Discussion

SATURDAY, NOVEMBER 16, 2019

5TH IPC SYMPOSIUM Advances in transplant

and cellular immunotherapy

FINAL PROGRAM 5TH IPC SYMPOSIUM Advances in transplant

and cellular immunotherapy

08.30 SESSION 7 – MICRO-TRANSPLANT Chairs: N-C. Gorin, Paris, France

& K. Liu, Beijing, China

08.30 Importance of donor source for microtransplant J. Hu, Shanghai, China

09.00 SPONSORED LECTURES Chairs: S. Bramanti, Milan, Italy

& S. Isaragrissil, Bangkok, Thailand

09.00 Advances in viral infection after Allo-HSCT D. Blaise, Marseille, France

09.30 Advances in liver toxicity after Allo-HSCT M. Mohty, Paris, France

10.00 Coffee break & exhibition visit

10.15 SESSION 8 – LYMPHOMA Chairs: J. El Cheikh, Beirut, Lebanon,

R. Gabus, Montevideo, Uruguay & Z. Peric, Zagreb, Croatia

10.15 Dose intensity in conditioning of Haplo-HSCT P. Chevallier, Nantes, France

10.45 Advanced lymphoma: best strategy? HSCT? Car T-cells A. Bazarbachi, Beirut, Lebanon

11.15 Advances in immunotherapy for Hodgkin lymphoma: monoclonal antibodies and Haplo-HSCT L. Castagna, Marseille, France

11.45 Discussion

12.00 SESSION 9 – PRACTICAL CONSIDERATIONS Chairs: K. Halaburda, Warsaw, Poland

F. Lorentino, Milan, Italy & R. Mohty, Beirut, Lebanon

12.00 Cardio toxicities in Haplo-HSCT R. Dulery, Paris, France

12.15 Sickle cell anemia: transplant and gene therapy S. Fürst, Marseille, France

12.30 HSCT in patients older than 70 years S. Harbi, Marseille, France

12.45 Summing-up

SUNDAY, NOVEMBER 17, 2019

ACKNOWLEDGMENTS

PLATINUM SPONSORS

GOLD SPONSORS

SILVER SPONSORS

SPONSORS


Recommended